Announcement of Domestic NDR... Q1 2026 Earnings and Business Update to Be Presented, No Direct Impact on Shareholder Value
SK Biopharmaceuticals will hold an NDR (small group meeting) for domestic institutional investors on May 27-28, 2026.
The main content includes Q1 2026 earnings and key business updates with Q&A, sponsored by Daol Investment & Securities.
This is part of routine IR activities and does not involve new capital raising or stock-related issues.
IR materials will be posted on the company's website on the same day.
[AI Comprehensive Analysis]This disclosure is a routine IR schedule announcement with no direct impact on stock price or corporate value. However, enhanced communication with institutional investors may contribute to reducing information asymmetry in the long term.